A revolutionary antibody approach for fighting cancer

Patrys’ deoxymab platform is based on unique, proprietary antibodies

Seek out cancer cells, wherever they are in the body

Naturally get inside cells and the cell nucleus

Cross the blood-brain barrier (BBB)

Inhibit DNA damage repair (DDR) allowing treatment of various cancers

Patrys is using these unique antibodies to develop revolutionary therapies for the treatment of cancer

Single agent therapies

To treat cancers with existing DDR deficiencies

Combination therapies

Using deoxymabs in combination with chemo or radiation therapies

Targeting agent

Delivers therapeutic payloads into the cell nucleus

Please click here to view our latest company presentation.

Please click here to find out more about investing in Patrys.

Level 4, 100 Albert Road
South Melbourne VIC 3205

ABN 97 123 055 363
Phone +61 3 9670 3273

Latest News